Mirels' Criteria for Prophylactic Fixation
ورودیهای بالینی بیمار
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- Low Risk4–7
- Intermediate Risk8–8
- High Risk9–12
The Mirels' Criteria for Prophylactic Fixation calculates predicting risk of pathologic fracture in patients with long bone metastasis to guide prophylactic fixation decisions. Key inputs include site of lesion. Scores guide adjusting systemic antineoplastic regimens, planning supportive palliative measures, or targeted monitoring. Routine clinical application promotes standardized evidence-based patient management.
Clinical Guidelines & Evidence
Predicts risk of pathologic fracture in patients with long bone metastasis to guide prophylactic fixation decisions
Clinical Indication
The Mirels' Criteria for Prophylactic Fixation is indicated for bedside clinical practice to support Predicts risk of pathologic fracture in patients with long bone metastasis to guide prophylactic fixation decisions. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients with solid tumors or hematologic malignancies undergoing staging, systemic therapy tolerability assessment, or prognostic stratification. Clinical application is indicated across Medical oncology clinics, chemotherapy infusion suites, inpatient oncology services, and palliative care.
Limitations & Contraindications
Prognostic indices provide statistical cohort survival estimates and must not replace individualized patient goals of care.
Clinical Pearls & Action Plan
Standardized functional performance status (ECOG or Karnofsky) is an independent determinant of chemotherapy tolerance and survival. Guideline pearl: Serial assessment may be needed for lesions receiving non-surgical treatment.
Sum of points: Site (1-3) + Size (1-3) + Nature (1-3) + Pain (1-3) = Total (4-12 points)
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| site_of_lesion | string | Yes | Location of the metastatic lesion within the long bone |
| size_of_lesion | string | Yes | Size of lesion relative to bone diameter on plain radiographs |
| nature_of_lesion | string | Yes | Radiographic appearance of the metastatic lesion |
| pain | string | Yes | Level of pain related to the lesion |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 4–7 | Low Risk | 0-4% fracture risk at 6 months |
| 8–8 | Intermediate Risk | 15% fracture risk at 6 months |
| 9–12 | High Risk | >33% fracture risk at 6 months |
Evidence-Based References (EBM)
- Mirels H. Metastatic disease in long bones. A proposed scoring system for diagnosing impending pathologic fractures. Clin Orthop Relat Res. 1989 Dec;(249):256-64.
- Van der Linden YM, Dijkstra PD, Kroon HM, Lok JJ, Noordijk EM, Leer JW, et al. Comparative analysis of risk factors for pathological fracture with femoral metastases. J Bone Joint Surg Br. 2004 May;86(4):566-73.
- Nazarian A, Entezari V, Villa-Camacho JC, Zurakowski D, Snyder BD. Treatment planning and fracture prediction in patients with skeletal metastasis with CT-based rigidity analysis. Clin Cancer Res. 2014 May 1;20(9):2465-73. doi: 10.1158/1078-0432.CCR-13-2966.DOI: 10.1158/1078-0432.CCR-13-2966
- Evans AR, Bottros J, Grant W, Chen BY, Damron TA. Mirels' rating for humerus lesions is both reproducible and valid. Clin Orthop Relat Res. 2008 Jun;466(6):1279-84. doi: 10.1007/s11999-008-0200-0.DOI: 10.1007/s11999-008-0200-0